Altimmune
Live price unavailable. Yahoo unofficial endpoint may be throttling or the ticker may be misconfigured.
loading 1-year chart…
1-year close · Yahoo Finance · daily interval
What they do in peptide space
Altimmune's pemvidutide is a dual GLP-1/glucagon receptor agonist — a different mechanism stack than the GLP-1/GIP class led by tirzepatide. Phase 2 data showed weight loss in a similar range to early-stage tirzepatide-class compounds with a notable secondary effect on liver fat (MASH/MASLD endpoints).
The glucagon-agonist component is the bet that distinguishes Altimmune. In theory, glucagon agonism increases energy expenditure and supports lipid mobilization — useful for metabolic-syndrome and fatty-liver indications where pure appetite suppression is incomplete. The risk is that glucagon agonism complicates glycemic control in diabetic patients, which would limit pemvidutide's diabetes utility.
Altimmune is also developing pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis), where the liver-fat-reduction signal from Phase 2 has positioned the molecule competitively against semaglutide's MASH program.
Recent mentions
Coming soon — no editorial coverage or FDA alert mentioning Altimmune in our index yet. Items will surface here as the news / FDA cron pipelines ingest them.